News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB) Exec Explains $55,000 Annual Cost of New Drug


4/5/2013 8:50:08 AM

Biogen Idec’s new multiple sclerosis pill is officially in the hands of patients, and they are footing a hefty bill. The pill, dubbed Tecfidera, is priced at $55,000 per year. Biogen (Nasdsaq: BIIB) has hinted at the possibility of manufacturing Tecfidera locally at its leased Eisai facility. In light of that, I asked Richard Francis, senior vice president of U.S. Commercial Operations at Biogen, to walk me through how Biogen prices its drugs.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES